



## COMPANY NEWSLETTER

April 2017

### MESSAGE FROM THE MANAGING DIRECTOR



Welcome to our second newsletter for 2017 – it has been a quarter of significant milestones for Proteomics International which we've highlighted in the following pages. We hope you appreciate this summary and also invite you to explore the links to our website for further news.

The key developments have centred on PromarkerD, our breakthrough predictive test for diabetic kidney disease.

Last month this was proclaimed as the world leading diagnostic test for this disease by the independent, global research house Frost & Sullivan. With over 415 million diabetics at risk of chronic kidney disease, the importance of bringing this potentially life-changing predictive test to market is clear. A major milestone in that process was the publication of our disruptive technology platform for diagnostics R&D, which we call Promarker, in the Journal of European Proteomics Association. This lays the foundation for future publications of the clinical data and provides important peer reviewed endorsement of Proteomics International's approach to biomarker discovery and validation. We look forward to expanding the application of Promarker™ to other areas of diagnostics.

Direct engagement with clients and stakeholders, both old and new, remains an essential objective for Proteomics International and we enjoyed fruitful trips to Singapore, Hong Kong, and Shanghai in March as part of AusBiotech's Asia roadshow. In May we have a trade mission to India, followed in June by a visit to the USA centred on the conference of the American Diabetes Association. Please get in touch if you would like to meet with us during these visits.

Lastly, it is with great sadness that we pay tribute to Proteomics International's co-founder Dr Bill Parker, who died suddenly in February. Farewell Bill, it was an honour and a pleasure.

Richard Lipscombe, PhD  
Managing Director

#### IN THIS ISSUE

- PromarkerD test validated by peer-reviewed scientific journal**
- The Promarker™ platform**
- Comprehensive update on PromarkerD**
- Independent report identifies PromarkerD as world leading test**
- Upcoming events: India Trade Visit PromarkerD at ADA**
- Independent Investment Research (IIR) initiated coverage**
- In memory of Dr Bill Parker**



## PromarkerD test validated by peer-reviewed scientific journal


The PromarkerD diagnostic test for diabetic kidney disease achieved an important validation step with the publication of data underpinning the test. The publication in February followed an independent review by scientific experts and provides a validation of the test and its global applicability.

The published research proves the efficacy of the process used to develop and test Proteomics International's PromarkerD protein 'fingerprint' that detects the onset of kidney disease in patients with diabetes, to produce a novel diagnostic test that outperforms current gold standards (the ACR and eGFR tests). It was published in the peer-reviewed scientific journal *EuPA Open Proteomics*, the official journal of the European Proteomics Association (EuPA).

"*Comprehensive Mass Spectrometry Based Biomarker Discovery And Validation Platform As Applied To Diabetic Kidney Disease*" - click [here](#) for article and a short animation highlighting the key findings.

## The Promarker™ platform


Proteomics International's diagnostic research is made possible by the company's proprietary biomarker discovery platform termed Promarker™, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing. The technology is highly versatile and can be used to identify fingerprints from any biological source.



"Promarker" has been registered as a trademark in Australia and is pending in multiple other major jurisdictions.

## Comprehensive update on PromarkerD commercialisation progress

Proteomics International released a detailed update on commercialisation progress for its predictive diagnostic test PromarkerD. The detailed update covers receipt of the first licensing income for PromarkerD, key patents secured and market size, study results and licensing discussions, and lays out the timeline for clinical laboratory prototype manufacture and first commercial sales of the test.



## Independent report identifies PromarkerD as world leading test for diabetic kidney disease

An independent report by respected research house Frost & Sullivan singled out Proteomics International as the world leader in diagnostics for diabetic kidney disease. The March report, titled *Biomarkers Enabling Diabetes and Obesity Management*, says novel biomarker research "is likely to transform the future of obesity and diabetes management". It goes on to highlight PromarkerD, Proteomics

International's novel test for diabetic kidney disease, noting its "high adoption potential". There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest Proteomics International is one of only two companies in the world developing such a test.

---

**Proteomics International presenting PromarkerD at the  
American Diabetes Association (ADA) 77<sup>th</sup> Scientific Sessions  
June 9-13, San Diego CA**

---





## Proteomics International India Trade Visit May 8-12

■ Ahmedabad ■ Baroda ■ Pune ■ Mumbai

Please visit our [website](#) for more info.

**Come join us for a relaxed evening of networking over food and refreshments**

**Friday, 12<sup>th</sup> May – Mumbai – Biosimilars, Biologics and Biomarker Discovery**

Opening remarks by **Australian Trade Commissioner**

*Featured Speakers:*

**Dr. K. Bangarurajan** – Dy. Drugs Controller (India), **CDSCO West Zone**

**Dr. Venkata Ramana** – Chief Scientific Officer, **Reliance Life Sciences Pvt. Ltd**

**Dr. Richard Lipscombe** – Managing Director, **Proteomics International**

**Unison III Banquet Hall, Four Points by Sheraton Hotel**

## Independent Investment Research (IIR) initiated coverage

IIR is an independent investment research house based in Australia and the United States specialising in the analysis of high quality commissioned research for Brokers, Family Offices and Fund Managers. The IIR report reviews the Proteomics International business model and concludes there is significant discount in the company's current valuation based on sum of parts and risk adjusted valuation models.



The report further stated “the breakthrough diagnostic test (PromarkerD) has the potential to provide Proteomics International with significant upside value”, and went on to reflect “the potential (of PromarkerD) to reduce the occurrence of kidney failure in diabetics and reduce the billions of dollars spent on the treatment of chronic kidney disease worldwide.” Click [here](#) to view a copy of the research report.



*Vale William (Bill) Parker  
1944-2017*

### IN MEMORY OF **William Frederick Parker** 26th Jan 1944 – 13th Feb 2017

On 13 February this year, Proteomics International and the Western Australia biotechnology industry lost one of its stalwarts, Dr Bill Parker. Bill was active in the sector for more than 40 years, and was very much a pioneer in the development of biotech in the state.

In 1982, he established Western Biotechnology with career-long colleagues Terry Sweet and Dr John Dunlop (both now current directors of Proteomics International). The company, which was then the world's only producer of natural beta-carotene from algal lakes, was acquired by Hoffmann La Roche, and the plant is still operating today.

In 2001, Bill co-founded Proteomics International with Dr Richard Lipscombe (now ASX listed as PIQ). Bill served as a director throughout the company's development, only retiring from the board in 2016. Never one to sit still, he remained an active contributor right up until the day he died peacefully in his sleep, aged 73.

Bill was committee member of the Western Australia Branch of AusBiotech for several years, and long-time mentor to students at the University of Western Australia. His innovation also extended to renewable energy as the editor of the Australian Solar Council's industry magazine for 19 years. Bill was indeed a gentleman of many talents, from microbiologists to writer, photographer, musician, actor, classic car revhead, rower, volunteer firefighter, and Morris dancer. After nearly 20 years working together, Richard eloquently summed him up: 'Bill had an uncanny ability to think outside the box, and boundless enthusiasm for life's opportunities'. He will be greatly missed by all those who knew him.

*Adapted from Australasian BioTechnology | April 2017 | Volume 27 | Number 1*



## PROTEOMICS – FAST FACT PANEL

### COMPANY CONTACTS

**Dr Richard Lipscombe**  
Managing Director

**Mr Chuck Morrison**  
Head of Business Development

**Ms Andreja Livk**  
Contract Services Manager

**Dr Scott Bringans**  
Research Manager

**Ms Sue Wong**  
Business Development

**Dr Pearl Tan**  
Chief Operating Officer

### AGENTS

#### India

Proteomics International – India  
[www.proteomicsindia.com](http://www.proteomicsindia.com)  
[info-india@proteomics.com.au](mailto:info-india@proteomics.com.au)  
T: + 91 8527 699 192

#### Malaysia/ Indonesia/ Thailand

First BASE Laboratories S/B  
[www.base-asia.com](http://www.base-asia.com)  
[peptide-my@base-asia.com](mailto:peptide-my@base-asia.com)  
T: + 603 8943 3252

#### Singapore

Axil Scientific Pte Ltd  
[www.axilscientific.com](http://www.axilscientific.com)  
[peptide@axilscientific.com](mailto:peptide@axilscientific.com)  
T: + 65 6775 7318

#### Japan

Leave a Nest Co. Ltd  
[www.leaveanest.com](http://www.leaveanest.com)  
[info@leaveanest.com](mailto:info@leaveanest.com)  
T: + 81 3 6277 8041

#### Hong Kong/ China

Asia Bio Channel Limited  
[www.asiabiochannel.com](http://www.asiabiochannel.com)  
[bcoissac@asiabiochannel.com](mailto:bcoissac@asiabiochannel.com)  
T: + 852 9845 4791

#### Latin America

LinkPharma LLC  
[www.linkpharma.co](http://www.linkpharma.co)  
[customerservice@linkpharmaus.com](mailto:customerservice@linkpharmaus.com)  
T: +1 813 319 3972

#### Listing

Australian Securities Exchange

#### Market Capitalisation based on share price of 20 cents

A\$11.8 million

#### Stock Code

ASX: PIQ

#### Cash Position

A\$1.8 million (30/03/2017)

#### Issued Capital – Ordinary shares

59.0 million


Proteomics International is a wholly owned subsidiary of Proteomics International Laboratories Limited (ASX: PIQ).

## FOR FURTHER INFORMATION PLEASE CONTACT:

Proteomics International Laboratories Limited

 +61 8 9389 1992

 [info@proteomics.com.au](mailto:info@proteomics.com.au) (general)  
[bd@proteomics.com.au](mailto:bd@proteomics.com.au) (business development)

 [www.proteomics.com.au](http://www.proteomics.com.au)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

 QEII Medical Centre  
6 Verdun Street, Nedlands  
Perth WA 6009 Australia

### Forward looking statement

Any forward looking statements in this newsletter have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors many of which are outside Proteomics International Laboratories Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this newsletter include known and unknown risks. As actual results may differ materially to any assumptions made in this newsletter, you are urged to view any forward looking statements contained in this newsletter with caution. This newsletter should not be relied on as a recommendation or forecast by Proteomics International Laboratories Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.